Fundraising Fox
/Companies
Sign in

ARTBIO

Oslo, NO · Founded 2021 · 9 known investors

Find your way into ARTBIO

Sign up to see every warm intro you have to ARTBIO

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the ARTBIO team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue. The company covers the design, manufacture, and distribution of its therapies and builds on radiation research from the University of Oslo and Norway's Radium Hospital.

BiotechHealthtechMedical Devices

Founders & leadership

ARTBIO was founded in 2021 by Roy Larsen and Øyvind Bruland.

RLRoy Larsen
Roy LarsenScientific Co-Founder
ØB
Øyvind BrulandScientific Co-Founder; SAB Chairman
MY
Margaret YuChief Medical Officer
PD
Philippe DasseChief Technical Officer
ADAmra Demirovic
Amra DemirovicChief Human Resources Officer
NHNicole Hadas
Nicole HadasChief Legal Officer
JVJordi Vall-llosera Ferran
Jordi Vall-llosera FerranChief Quality Officer
JEJonathan E. Freeman
Jonathan E. FreemanChief Executive OfficerFounder at Healthcare North America Growth Stage
JF
Jonathan Freeman, Ph.DInterim CEO

Investors · 9

B4 Capitallisted by B4 Capital$10M – $50M
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · a partner's Signal profile · prnewswire.com · Not right? Tell us

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: a partner's Signal profile · funding news · prnewswire.com · the VCSheet dataset · sofinnova.com · open dataset · 5k.vc investor directory · Not right? Tell us

AlexandriareportedPasadena

How we know: prnewswire.com · Not right? Tell us

B Capitalreported

How we know: prnewswire.com · Not right? Tell us

Omega FundsreportedBoston

How we know: prnewswire.com · Not right? Tell us

Qatar Investment AuthorityreportedDoha

How we know: prnewswire.com · Not right? Tell us

Third Rock VenturesreportedBoston · $100K – $5M

How we know: a partner's Signal profile · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

$132M disclosed across 1 of 2 rounds · 2023–2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructureprnewswire.com · Jul 2025ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapiesprnewswire.com · Dec 2023

Frequently asked questions

What does ARTBIO do?
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue. The company covers the design, manufacture, and distribution of its therapies and builds on radiation research from the University of Oslo and Norway's Radium Hospital.
Who founded ARTBIO?
ARTBIO was founded by Roy Larsen, Øyvind Bruland in 2021.
Who are ARTBIO's investors?
ARTBIO's investors include B Capital Group, B4 Capital, F-Prime Capital, Sofinnova Ventures, Alexandria, B Capital, Omega Funds, Qatar Investment Authority and 1 more.
How much funding has ARTBIO raised?
ARTBIO has disclosed $132M raised across 1 of its 2 known rounds.
Where is ARTBIO headquartered?
ARTBIO is headquartered in Oslo, NO.